AiCuris is a global biopharmaceutical company that specializes in creating innovative treatments for severe infectious diseases, particularly for patients with compromised immune systems. Their work primarily involves the development and commercialization of new therapeutic candidates. Their target market includes patients who are at high risk of infection and have limited treatment options, such as those who have undergone stem cell or kidney transplants.

AiCuris operates by developing a portfolio of unique product candidates, conducting research, and running clinical trials to bring these potential treatments to market. Their business model revolves around the commercialization of these treatments, which generates revenue for the company.

One of their successful products is PREVYMIS® (letermovir), an antiviral agent used to prevent cytomegalovirus (CMV) reactivation in transplant patients. This product is marketed by MSD (Merck & Co., Inc.), and its sales contribute to AiCuris' increasing revenues.

Another promising product is Pritelivir, a treatment for acyclovir-resistant herpes simplex virus (HSV) infections in immunocompromised patients. This product is currently in phase 3 development and has received FDA breakthrough designation, indicating its potential for expedited development and review.

AiCuris also has an innovative pipeline of anti-infectives in development, including an anti-sense oligonucleotide (ASO) AIC468 for preventing BK virus (BKV) infection in kidney transplant patients.

In summary, AiCuris is a financially stable biopharmaceutical company with a strong management team. They are committed to becoming a fully integrated company, covering everything from research and clinical development to commercialization.

Keywords: Biopharmaceutical, Infectious Diseases, Immunocompromised Patients, Therapeutic Candidates, Clinical Development, Antiviral Agent, Cytomegalovirus (CMV), Herpes Simplex Virus (HSV), Anti-sense Oligonucleotide (ASO), BK Virus (BKV).